Moderna Inc
MRNA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$544.00 | Kxdx | Hwtqlhgts |
Moderna's mRNA Technology Looks Useful Beyond COVID-19, and the Firm Is Building a Moat
Business Strategy and Outlook
Moderna's mRNA technology has gained rapid validation as sales of its COVID-19 vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape for innovative vaccines.